Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing medicines for serious women’s health infections, with an office in Old Greenwich announced last week the results of a Phase 1 clinical program for its lead product candidate SYM-1219.
According to the results, a single oral dose of SYM-1219 is safe, well tolerated and had predictable pharmacokinetics (PK) for the treatment of bacterial vaginosis (BV). Symbiomix is advancing SYM-1219 with the goal of bringing it to market as the first single-dose oral treatment in the United States for the treatment of bacterial vaginosis (BV).
Affecting more than 20 million women annually, BV is the most common gynecological infections in the U.S. If left untreated, BV can cause serious health problems including pre-term birth and an increased risk of STDs, including HIV.
